The Molecular Disease

Linus Pauling and his colleagues showed in 1949 that the hemoglobin of sickle-cell patients was physically different from normal hemoglobin—it carried a different electric charge, migrated differently in an electrophoretic field, and was the direct cause of the distorted red cells that clog vessels and starve tissue. They named the result a “molecular disease,” and the phrase inaugurated an entire way of thinking: that illness is not merely a disturbance of physiology but a consequence of molecular structure, and that a change in a single molecule can alter the fate of the organism that carries it. The logic—structure determines function; a changed structure changes fate—is now the operating premise of AI-driven drug discovery, which uses the protein-structure predictions of systems like AlphaFold to design molecules that bind and block disease targets. Pauling drew the first such line by hand for one disease; the machines now draw millions in an afternoon, tracing the path from sequence to structure to consequence at